Intermittent inotrope infusion for end stage heart failure in Duchenne muscular dystrophy.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Neuromuscular Disorders

• Publication date

  2008-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.nmd.2008.09.002PMID 18952428
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Treatment of the heart in Duchenne muscular dystrophy

  2006cited by this paper
• Outpatient continuous inotrope infusion as an adjunct to heart failure therapy in Duchenne muscular dystrophy.

  2006influential reference
• Phosphodiesterase III inhibitors for heart failure.

  2005influential reference
• Respiratory care of the patient with Duchenne muscular dystrophy: ATS consensus statement.

  2004cited by this paper
• Long-term intermittent dobutamine infusion, combined with oral amiodarone for end-stage heart failure: a randomized double-blind study.

  2004influential reference
• 107th ENMC international workshop: the management of cardiac involvement in muscular dystrophy and myotonic dystrophy. 7th-9th June 2002, Naarden, the Netherlands.

  2003cited by this paper

• Myopathology of Congenital Myopathies: Bridging the Old and the New.

  2019cites this paper
• An adult with a rare form of congenital fiber type disproportion

  2018cites this paper
• Myopathy-causing Q147P TPM2 mutation shifts tropomyosin strands further towards the open position and increases the proportion of strong-binding cross-bridges during the ATPase cycle.

  2016cites this paper
• Gene Discovery in Congenital Myopathy

  2016cites this paper
• A novel TPM2 gene splice-site mutation causes severe congenital myopathy with arthrogryposis and dysmorphic features

  2016cites this paper
• Muscle fiber type disproportion (FTD) in a family with mutations in the LMNA gene

  2015cites this paper
• Approach to the diagnosis of congenital myopathies.

  2014cites this paper
• Congenital myopathies with secondary neuromuscular transmission defects; a case report and review of the literature.

  2014cites this paper
• Frequency and phenotype of patients carrying TPM2 and TPM3 gene mutations in a cohort of 94 patients with congenital myopathy.

  2014cites this paper
• The E117K mutation in β-tropomyosin disturbs concerted conformational changes of actomyosin in muscle fibers.

  2014cites this paper
• K7del is a common TPM2 gene mutation associated with nemaline myopathy and raised myofibre calcium sensitivity.

  2013cites this paper
• Recessive MYL2 mutations cause infantile type I muscle fibre disease and cardiomyopathy.

  2013cites this paper
• Digenic mutational inheritance of the integrin alpha 7 and the myosin heavy chain 7B genes causes congenital myopathy with left ventricular non-compact cardiomyopathy

  2013cites this paper
• Phenotypes of Myopathy-Related Beta-Tropomyosin Mutants in Human and Mouse Tissue Cultures

  2013cites this paper
• Genetics of Muscle Disease

  2013cites this paper
• Mutations in TPM2 and congenital fibre type disproportion.

  2012cites this paper
• Whole-Body muscle MRI in a series of patients with congenital myopathy related to TPM2 gene mutations.

  2012cites this paper
• Myopathies associated with β-tropomyosin mutations.

  2012cites this paper
• Congenital fiber-type disproportion.

  2011cites this paper
• Current world literature.

  2009cites this paper
• Cap disease due to mutation of the beta-tropomyosin gene (TPM2).

  2009cites this paper